Designing an ATMP manufacturing facility: from concept to completion

Remy Martin, business development specialist at cell and gene therapy manufacturing consultant, eXmoor Pharma, discusses 10 key considerations when creating a manufacturing facility, to ensure it meets requirements for both immediate needs and future growth.

NEW ADVANCED therapy medicinal product (ATMP) manufacturing facilities represent significant capital investment. By taking an approach that addresses a facility’s production and output obligations, stakeholders can make informed decisions that will lead to a successful construction and long-term operation.

The following aspects should be assessed before a site is agreed, to reinforce the project’s long‑term success. While many of these are concurrent considerations, often one or more go under‑scrutinised during the planning process.